In a nutshell
This study looked at the effects of dulaglutide (Trulicity) on erectile function in men with type 2 diabetes (T2D). It found that men with T2D taking dulaglutide were less likely to develop erectile dysfunction (ED) than those taking a placebo.
Some background
ED is a common complication of T2D. It involves an inability to get or keep an erection firm enough for intercourse. It is not known if diabetic treatments can help to prevent ED as effectively as they prevent other complications.
Dulaglutide is a diabetic treatment that increases natural insulin production. It also slows the rate at which the stomach empties, helping to control blood sugar levels after a meal. It is not known whether it has any effect on erectile function in men with T2D.
Methods & findings
3,725 men with T2D participated in this study. Participants were asked to fill in questionnaires about their erectile function at the start of the study and again after 2 years, 5 years, and at the end of the study. 1,872 patients were treated with dulaglutide. 1,853 patients were treated with a placebo.
56.5% of participants had moderate to severe ED at the start of the study. ED was on average 8% less likely to occur in the dulaglutide group compared to the placebo group. In men who already had ED, there was a lower risk of worsening of ED in the dulaglutide group compared to the placebo group.
The bottom line
This study showed that dulaglutide may help to prevent or stop the progression of erectile dysfunction.
The fine print
This study was funded by Eli Lilly and Company, the manufacturer of dulaglutide.
Published By :
The lancet. Diabetes & endocrinology
Date :
Jun 18, 2021
